icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

‘Sputnik Light’: Testing of single-dose anti-Covid vaccine based on ‘Sputnik V’ kicks off in Russia

‘Sputnik Light’: Testing of single-dose anti-Covid vaccine based on ‘Sputnik V’ kicks off in Russia
Trials of a simplified version of the Sputnik V coronavirus vaccine have begun in Russia. While providing less protection, the solution is expected to be easier to distribute and use in emergency mass-vaccination scenarios.

Trials of the vaccine variant, dubbed ‘Sputnik Light,’ kicked off in Russia on Friday, according to the updated national register of medical drugs. It says the first stage of trials will involve some 150 people who have volunteered to get the express shot. The testing will take place at three medical facilities, located in Moscow and St. Petersburg. 

Unlike the Sputnik V vaccine, which is administered in two doses two weeks apart, the light version comes in the form of a single shot. The new anti-coronavirus solution is basically one of the two components of the original Sputnik V, head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev told RT in December. While it offers weaker protection for a shorter period of time compared to the two-dose Sputnik V, it comes in handy as a stopgap solution to major outbreaks. 

“It’s sort of like a seasonal flu vaccine… You take it before winter and it protects you over the winter. This is what Sputnik V Light would be doing,” Dmitriev explained.

Also on rt.com Deal with AstraZeneca shames ‘unethical’ attackers of Sputnik V & should inspire cooperation – funder of Russian vaccine tells RT

The simplified solution is expected to have some 85 percent efficacy, Alexander Gintsburg, head of the Moscow Gamaleya Institute which developed the pioneering vaccine, told Russia 24 TV channel last month. This is compared to the latest efficacy estimate of 91.4 percent of the two-dose Sputnik V.

The light version will also provide immunity for a shorter period of time, estimated at three to four months. At the same time, it is believed that even if the vaccine fails to shield the recipient from Covid-19 entirely, a vaccinated individual would experience the coronavirus only in its milder form. Another perk of the light version is that a vaccinated person can get the second component of Sputnik V some three months after the first shot, Gintsburg explained.

It is understood that the light version of the vaccine will only be exported to countries in need, while Russian citizens will continue receiving the regular two-dose Sputnik V. The vaccine’s manufacturers are set to accelerate its production, with some four million doses expected to be produced within the next month, Gintsburg told Russian media on Monday.

Also on rt.com Palestine approves Russia’s Sputnik V vaccine ahead of others in Middle East

Think your friends would be interested? Share this story!

Podcasts